Speaker/Presentation

Time in EDT

Mita Manna (Chair)

Describe REAL Alliance’s purpose, including its impact on policy change

6:00–6:10 p.m.

Katarzyna J. Jerzak / Mita Manna

HER2+: Apply recommendations for early and metastatic disease [Kumar et al., 2026]

Neoadj pertuzumab DB05 and 11 [MM]

1L options, induction DEMETHER, brain mets [KJJ]

6:10–6:25 p.m.

Katarzyna J. Jerzak / Mita Manna 

HR+HER2- Early: Apply recommendations for early [Sehdev et al., 2026]

Adjuvant CDK4/6i [NL]

OFSET, SOFT/TEXT CCTG [MM]

6:25–6:35 p.m.

Katarzyna J. Jerzak/Nathalie Levasseur

HR+HER2- Metastatic: Apply recommendations for metastatic disease [Jerzak et al., 2026]

De novo – ribo / abema;  what if rapid relapse INOVA120, monitoring protocol

6:35–6:45 p.m.

Nathalie Levasseur / Katarzyna J. Jerzak

TNBC: Apply recommendations for early and metastatic disease [Simmons et al., 2026] 

KN522, CCTG MA29 / ADC TROP2 to 1L / Dato / toxicity / sequencing (Huppert on sequencing)

6:45–7:00 p.m.

Q&A Session

7:00–7:15 p.m.

Mita Manna (Chair)

Closing of Webinar

7:15–7:25 p.m.